319,663 Shares of Sensei Biotherapeutics, Inc. $FTH Acquired by Candriam S.C.A.

Key Points

• Candriam S.C.A. acquired 319,663 Sensei Biotherapeutics shares in the third quarter, valued at about $9.54 million and representing roughly 1.24% of the company.
• Sensei reported a quarterly loss of $0.79 per share, missing analyst expectations of a $0.66 loss; analysts expect a full-year loss of $13.35 per share.
• Analyst sentiment was generally positive: the stock had a “Moderate Buy” consensus rating and an average price target of $56.17.

Candriam S.C.A. purchased a new stake in Sensei Biotherapeutics, Inc. (NASDAQ:FTH - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 319,663 shares of the company's stock, valued at approximately $9,542,000. Candriam S.C.A. owned approximately 1.24% of Sensei Biotherapeutics as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Vivo Capital LLC bought a new stake in Sensei Biotherapeutics in the 1st quarter valued at about $22,758,000. Stempoint Capital LP bought a new position in shares of Sensei Biotherapeutics during the first quarter worth approximately $4,188,000. Alyeska Investment Group L.P. bought a new position in shares of Sensei Biotherapeutics during the second quarter worth approximately $3,610,000. Bank of America Corp DE increased its holdings in shares of Sensei Biotherapeutics by 10,692.5% during the first quarter. Bank of America Corp DE now owns 33,025 shares of the company's stock worth $1,041,000 after purchasing an additional 32,719 shares during the period. Finally, Renaissance Technologies LLC raised its position in shares of Sensei Biotherapeutics by 178.2% in the first quarter. Renaissance Technologies LLC now owns 32,041 shares of the company's stock valued at $1,010,000 after buying an additional 20,525 shares in the last quarter. 10.50% of the stock is owned by institutional investors.

Sensei Biotherapeutics Price Performance

NASDAQ FTH opened at $12.68 on Tuesday. Sensei Biotherapeutics, Inc. has a 1 year low of $7.45 and a 1 year high of $42.14. The firm has a market cap of $327.65 million, a price-to-earnings ratio of -0.09 and a beta of -0.15. The stock's 50 day moving average price is $27.04.

Sensei Biotherapeutics (NASDAQ:FTH - Get Free Report) last released its earnings results on Tuesday, November 3rd. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.13). Equities research analysts predict that Sensei Biotherapeutics, Inc. will post -13.35 earnings per share for the current year.

Wall Street Analyst Weigh In

FTH has been the subject of several recent research reports. William Blair assumed coverage on Sensei Biotherapeutics in a research note on Friday, October 16th. They issued an "outperform" rating for the company. Oppenheimer began coverage on Sensei Biotherapeutics in a research note on Tuesday, July 28th. They set an "outperform" rating and a $60.00 price objective on the stock. Citizens Jmp began coverage on Sensei Biotherapeutics in a report on Monday, July 20th. They issued an "outperform" rating and a $51.00 price objective for the company. JonesTrading initiated coverage on Sensei Biotherapeutics in a research report on Tuesday, August 4th. They set a "buy" rating and a $55.00 target price for the company. Finally, Needham & Company LLC assumed coverage on Sensei Biotherapeutics in a research report on Friday, August 21st. They set a "buy" rating and a $56.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Sensei Biotherapeutics currently has an average rating of "Moderate Buy" and an average price target of $56.17.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company's research is designed to activate and direct the immune system against tumors, with an emphasis on treatments that may address immune-suppressive mechanisms in the tumor microenvironment.

Sensei's pipeline has included SNS-101, an investigational antibody targeting VISTA, an immune checkpoint believed to limit anti-tumor immune responses, and SNS-301, an investigational cancer vaccine developed using the company's ImmunoPhage platform.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.